Pregnancy Clinical Trial
Official title:
Women Specific Cardiac Recovery After Preeclampsia
Pregnancy is considered a cardiovascular (CV) stress test, and complicated pregnancies are associated with an increased risk for cardiovascular disease (CVD) later in life. Moreover, it is known that often the pregnancy induced CV adaptation does not resolve completely after a short postpartum (PP) period and it is not clear whether these induced changes will resolve over a longer period of time (i.e. in the upcoming months/years after delivery). Understanding the cardiac adaptation during pregnancy and the reversal process in the postpartum period, as well as the factors that influence this these processes, may provide us not only insight in this mechanism, but may help us in identifying factors that may be target points for modification.
The main goal of this study is to explore the pattern of physiologic and pathophysiologic
cardiac recovery after a preeclamptic pregnancy compared to a normotensive pregnancy, up till
18 months PP.
This study is a longitudinal cohort study. The first measurement will be performed upon
admittance for induction of labour or caesarean section, which corresponds with 48-24 hours
before delivery. Further measurements will be performed in clusters at PP intervals of: 24-48
hours, 3 weeks, 6 weeks, 3 months, 6 months, 12 months and 18 months. Cases will also receive
an additional baseline measurement upon PE diagnosis.
Cases consist of women with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy
(early and late PE, with or without intra uterine growth restriction (IUGR)), whereas
controls are women with an uncomplicated pregnancy. 290 women in total will be included.
Inclusion will of case subjects will occur upon diagnosis, inclusion of controls will occur
before delivery.
The first visit of this study will be performed upon admittance after PE diagnosis for cases,
and for controls while the participant is administered for the induction of labour or
caesarean section, thus an extra visit is not necessary. This is also true for the first
postpartum (PP) measurements. The next 6 visits will be after the participant is discharged
from the hospital and extra visits are necessary, except for the 6 weeks PP visit, which is a
routine visit. The frequent visits may cause some discomfort, especially since our
participants are young mothers who still need to take care of their child. During the
measurement, one of our co-workers will assist in taking care of the newborn if necessary, so
that the participant can bring her child with her. Each of the visits will last approximately
2 hours in the MUMC+. The only invasive procedure is a venapunction where 75 ml blood will be
extracted. The only unfavourable side effect can be a small hematoma (rare). Clinically,
participants will be advised based on their risk profile following standard "cardiovascular
(CV) risk management". Transthoracic echocardiography, glycocalyx measurements and a
FibroScan will be performed. Experience shows that this investigation is not experienced as
uncomfortable. Also, 3 liters of exhaled air will be collected for VOCs analysis. All
measurements will be performed or supervised by an experienced researcher. These
investigations are already approved previously in other METC applications (CMO-nr: 2008/226;
2009/004; 10-2-066). The other measurements (questionnaires, blood pressure (BP), weight
measurement, urine collection, glycocalyx measurement, FibroScan and exhaled air collection)
do not cause any discomfort for the patient besides the time that it takes. On the other
hand, potential health improvement and early detection of CV risk profiles and initiation of
already existing effective prevention strategies that improve lifestyle are important
benefits.
For potential participants who find the number of extra visits too great a burden, a short
track version of the study is available with less postpartum visits. the first 3 measurement
moments do not differ between both versions. However, after the first PP measurement,
24-48hrs after delivery, they will only have one more additional visit at 12 months PP, but
we will include a coronary CTA, an MFD and carotid IMT measurement.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Completed |
NCT02528136 -
The Clinical Carbetocin Myocardium Trial
|
Phase 4 |